Research Update: Valeant Pharmaceuticals International Inc. Downgraded To 'BB-' On Acquisition Of Bausch&Lomb; Outlook Stable - S&P Global Ratings’ Credit Research

Research Update: Valeant Pharmaceuticals International Inc. Downgraded To 'BB-' On Acquisition Of Bausch&Lomb; Outlook Stable

Research Update: Valeant Pharmaceuticals International Inc. Downgraded To 'BB-' On Acquisition Of Bausch&Lomb; Outlook Stable - S&P Global Ratings’ Credit Research
Research Update: Valeant Pharmaceuticals International Inc. Downgraded To 'BB-' On Acquisition Of Bausch&Lomb; Outlook Stable
Published Jun 19, 2013
2333 words — Published Jun 19, 2013
Price US$ 225.00  |  Buy this Report Now

About This Report

  
Abstract:

Montreal-based Valeant is adding approximately $7.5 billion of debt to fund the acquisition of Bausch&Lomb (B&L) and to refinance B&L's debt. Pro forma adjusted leverage will increase to 5.7x (excluding synergies). We are lowering the corporate credit rating to 'BB-' from 'BB'. We are lowering our existing senior secured issue-level ratings to 'BB' from 'BBB-' and assigning a 'BB' issue-level rating to the proposed $4.050 billion of term loans. We are also lowering our existing senior unsecured issue-level rating to 'B' from 'BB-' and assigning a 'B' issue-level rating to the proposed $3.225 billion of senior unsecured notes. The stable outlook reflects our expectation that while credit metrics could improve, based on good free cash flow, the company's

  
Brief Excerpt:

RESEARCH Research Update: Valeant Pharmaceuticals International Inc. Downgraded To '##-' On Acquisition Of Bausch & Lomb; Outlook Stable Publication date: 19-Jun-2013 Primary Credit Analyst: Michael G Berrian, Boston (1) 617-530-8307;...

  
Report Type:

Research Update

Ticker
VRX
Issuer
GICS
Pharmaceuticals (35202010)
Sector
Global Issuers
Country
Region
Format:
HTML HTML
Buy Now

S&P Global Ratings’ Credit Research—S&P Global Ratings’ credit research provides analysis on issuers and debt obligations of corporations, states and municipalities, financial institutions, insurance companies and sovereign governments. S&P Global Ratings also offers insight into the credit risk of structured finance deals, providing an independent view of credit risk associated with a growing array of debt-securitized instruments.

About the Author


Cite this Report

  
MLA:
S&P Global Ratings’ Credit Research. "Research Update: Valeant Pharmaceuticals International Inc. Downgraded To 'BB-' On Acquisition Of Bausch&Lomb; Outlook Stable" Jun 19, 2013. Alacra Store. May 21, 2025. <http://www.alacrastore.com/s-and-p-credit-research/Research-Update-Valeant-Pharmaceuticals-International-Inc-Downgraded-To-BB-On-Acquisition-Of-Bausch-Lomb-Outlook-Stable-1147946>
  
APA:
S&P Global Ratings’ Credit Research. (). Research Update: Valeant Pharmaceuticals International Inc. Downgraded To 'BB-' On Acquisition Of Bausch&Lomb; Outlook Stable Jun 19, 2013. New York, NY: Alacra Store. Retrieved May 21, 2025 from <http://www.alacrastore.com/s-and-p-credit-research/Research-Update-Valeant-Pharmaceuticals-International-Inc-Downgraded-To-BB-On-Acquisition-Of-Bausch-Lomb-Outlook-Stable-1147946>
  
US$ 225.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.